Lichen Planus- Pipeline Insight, 2024

This “Lichen Planus- Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Lichen Planus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lichen Planus: Understanding

Lichen Planus: Overview

Lichen planus (LP) is a chronic inflammatory condition affecting the skin, mucous membranes, nails, and hair. It is characterized by distinctive, purplish, flat-topped bumps that can cause itching and discomfort. While the exact prevalence of LP is not well-documented, it is considered relatively common, affecting about 1-2% of the population, with a higher incidence in middle-aged adults. The condition is thought to be autoimmune in nature, although its precise cause remains unclear.

The hallmark of lichen planus is the presence of pruritic, polygonal, purple papules and plaques on the skin, commonly found on the wrists, lower back, and ankles. The lesions are often shiny and may have fine white lines on their surface, known as Wickham striae. When mucous membranes are involved, such as in the mouth (oral lichen planus), patients may experience white, lacy patches or painful sores. Other manifestations include nail changes like thinning or splitting, and hair loss in cases involving the scalp (lichen planopilaris).

The exact etiology of lichen planus is unknown, but it is believed to be an autoimmune disorder where the body's immune system mistakenly attacks its own tissues. Genetic predisposition and environmental factors, such as infections or medications, may trigger the condition. Pathophysiologically, LP involves an immune-mediated response that targets keratinocytes in the skin and mucous membranes. This response leads to apoptosis of these cells and the characteristic inflammation and lesions associated with the disease. T-cell lymphocytes are thought to play a central role in this immune response.

Diagnosis of lichen planus is primarily clinical, based on the characteristic appearance of the lesions and patient history. A skin biopsy can confirm the diagnosis by revealing typical histopathological features, such as a band-like lymphocytic infiltrate at the dermal-epidermal junction and hypergranulosis. Additional tests may be conducted to rule out other conditions with similar presentations.

Treatment of lichen planus aims to alleviate symptoms and manage inflammation. Topical corticosteroids are the first-line treatment for localized skin lesions, while systemic corticosteroids or other immunosuppressive agents may be necessary for more severe or widespread cases. For oral lichen planus, topical corticosteroids, retinoids, or calcineurin inhibitors are often used. Phototherapy can also be beneficial for extensive skin involvement. Although lichen planus can resolve on its own within several months to years, some cases can become chronic or recurrent, necessitating long-term management strategies. Regular follow-up is important to monitor for potential complications, including an increased risk of squamous cell carcinoma in chronic mucosal lesions.

"Lichen Planus- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lichen Planus pipeline landscape is provided which includes the disease overview and Lichen Planus treatment guidelines. The assessment part of the report embraces, in depth Lichen Planus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lichen Planus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lichen Planus R&D. The therapies under development are focused on novel approaches to treat/improve Lichen Planus.

Lichen Planus Emerging Drugs Chapters

This segment of the Lichen Planus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lichen Planus Emerging Drugs

LP-310: Lipella Pharmaceuticals

LP-310 is an oral rinse formulation intended for the treatment of oral lichen planus (OLP), a chronic, painful, inflammatory, pre-malignant, T-cell-mediated, autoimmune disease affecting the oral mucosa of approximately 6-7 million Americans. There is no approved pharmacotherapy and most currently available treatments are palliative. Lipella has received IND approval for a Phase IIa multicenter dose escalation trial evaluating the safety and efficacy of LP-10 in subjects with symptomatic OLP (link). Lipella expects to commence dosing the first patient in the summer of 2024. Currently, the drug is in Phase II stage of its development for the treatment of Lichen planus.

Lichen Planus: Therapeutic Assessment

This segment of the report provides insights about the different Lichen Planus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lichen Planus

• There are approx. 3+ key companies which are developing the therapies for Lichen Planus. The companies which have their Lichen Planus drug candidates in the most advanced stage, i.e. phase II include, Lipella Pharmaceuticals.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lichen Planus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lichen Planus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lichen Planus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lichen Planus drugs.

Lichen Planus Report Insights

• Lichen Planus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lichen Planus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lichen Planus drugs?
• How many Lichen Planus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lichen Planus?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lichen Planus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lichen Planus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lipella Pharmaceuticals
• Incyte
• AFYX Therapeutics

Key Products

• LP-310
• Ruxolitinib cream
• AFYX-005

This product will be delivered within 2 business days.